This longitudinal study develops and validates a blood plasma–based biological staging model for Alzheimer disease that closely mirrors an amyloid and tau positron emission tomography–based staging sy...

imageimageMachine-learning models using CSF and plasma biomarkers accurately predicted quantitative Aβ-PET burden. Distinct contributions of soluble Aβ42/Aβ40 and plasma P-tau217 reveal their role in ...

This cohort study evaluates the use of plasma phosphorylated tau 217 in identifying preclinical Alzheimer disease in individuals with amyloid β pathology.

New publication in Nature Medicine!   In this study, led by PhD students Pontus Tideman and Linda Karlsson, we demonstrate that a brief, self-administered cognitive test battery can reliably identify ...

Baseline and longitudinal plasma p-tau217 were associated with subsequent decline in global cognition, progression to dementia, and increased tau burden, whereas baseline p-tau217 and GFAP were associ...

A simpler method of analysing blood samples for Alzheimer’s disease has been tested in a large multicentre study, led by Lund University in Sweden.

Among 1,767 patients in 5 centers, a fully automated blood test showed high accuracy for Alzheimer’s pathology in secondary and primary care using a predefined cutoff.

Plasma eMTBR-tau243 is a specific biomarker of tau tangles in Alzheimer’s disease and enables the detecting and tracking of Alzheimer’s clinical impairment.

The test, which is not yet commercially available, focuses on a different form of the protein tau.